Oxytocin receptor antagonist treatment in luteal phase for implantation and pregnancy in women with reproductive medicine

摘要

The present invention relates to the use of oxytocin receptor antagonists in females in which embryo transfer is performed as part of assisted reproductive medicine. In particular, there is provided a method for increasing the in-process implantation rate, increasing the ongoing pregnancy rate, increasing the clinical pregnancy rate, and / or increasing the fertility rate in a female subject in which embryo implantation is performed. Specifically, the antagonist is released into the luteal phase when the endometrium receives embryo implantation and / or when the embryo reaches blastocyst stage.